On August 12, 2026, Oscar Health Inc OSCR shares rose 5.9% to a current price of $29.61. The stock has experienced a significant increase year-to-date, up 106.0%, although it has faced some volatility in the near term, with a 52-week range of $10.69 to $33.10.
- GF Valueâ„¢ verdict: Current price is $29.61, which is 38.6% above the GF Valueâ„¢ estimate of $21.36, indicating the stock is overvalued.
- GF Scoreâ„¢ of 76/100 suggests that Oscar Health is in the above-average range in terms of overall financial health and potential.
- Notable signal: Insiders have sold $109.4M worth of shares in the last three months, with no buying activity.
Is OSCR Overvalued or Undervalued?
The current market price of Oscar Health Inc OSCR at $29.61 stands significantly above the GF Valueâ„¢ estimate of $21.36, marking the stock as 38.6% overvalued. The GF Valueâ„¢ is GuruFocus' proprietary estimate of the intrinsic value of a stock, which is derived from a combination of historical trading multiples, past business growth, and future performance projections. This valuation suggests that investors are currently paying a premium for the stock compared to its estimated fair value, which raises concerns about a margin of safety for potential investors.
Given that the GF Valuation label categorizes the stock as significantly overvalued, this poses a risk for current shareholders. If the market corrects itself or if the company fails to meet growth expectations, the stock price could decline, highlighting the importance of careful consideration before entering or adding to a position in OSCR.
How Does OSCR's Valuation Compare to Its History?
| Metric | Current | Historical |
|---|---|---|
| P/E (TTM) | 21.1x | 45.7x (5-Year Median) |
| Forward P/E | 25.8x | N/A |
Oscar Health's current P/E ratio of 21.1x is significantly below its 5-year median P/E of 45.7x, suggesting that the stock is trading at a lower valuation compared to its historical average. However, this analysis aligns with the GF Valueâ„¢ verdict of being overvalued, as the price remains elevated despite a low P/E ratio compared to its past. The forward P/E of 25.8x also indicates expected growth, but investors should be cautious given the current overvaluation status.
What Does OSCR's GF Scoreâ„¢ Tell Us?
The GF Scoreâ„¢ is a comprehensive measure that evaluates a stock's financial strength, profitability, growth potential, valuation, and momentum. Oscar Health has a GF Scoreâ„¢ of 76/100, indicating it is above average in terms of financial health and investment potential. Its strongest sub-rank is in momentum, scoring 9/10, which reflects its impressive price performance over the past year. However, its weakest area is in profitability, where it has a score of 4/10, indicating challenges in generating consistent profits.
| Metric | Rating |
|---|---|
| GF Scoreâ„¢ | 76/100 |
| Financial Strength | 7/10 |
| Profitability | 4/10 |
| Growth | 7/10 |
| Valuation | 5/10 |
| Momentum | 9/10 |
In summary, while Oscar Health shows a strong momentum score, indicating positive price trends, its lower profitability rank suggests that the company may face challenges in sustaining its growth. This combination of scores offers insights into the company's overall health, highlighting both strengths and areas for improvement.
What Are Gurus and Insiders Doing with OSCR?
Currently, four gurus hold shares of Oscar Health, with four adding to their positions and two trimming their holdings in recent quarters. This indicates a generally positive sentiment among institutional investors. However, the insider selling of $109.4M in shares over the last three months, without any insider buying, raises concerns about the company's outlook from those who are closest to its operations.
The significant insider selling could signal a lack of confidence from management or insiders regarding the company's near-term prospects. This pattern suggests that while institutional interest may be growing, insiders are taking the opportunity to cash out, which could lead to increased volatility in the stock price moving forward.
What This Means for Investors
In conclusion, Oscar Health Inc OSCR appears to be overvalued based on the GF Valueâ„¢ analysis, with a current price significantly higher than the estimated fair value. The combination of a strong momentum rank and insider selling presents a mixed picture for potential investors, indicating the need for caution. For more detailed insights, you can visit the Oscar Health Inc (OSCR) stock page, as well as explore the GF Valueâ„¢ page for additional valuation metrics.
Frequently Asked Questions
What is OSCR's GF Scoreâ„¢?
Oscar Health has a GF Scoreâ„¢ of 76/100, indicating it is above average in terms of financial health and potential investment performance.
Is OSCR overvalued or undervalued?
Based on the GF Valueâ„¢ verdict, OSCR is currently overvalued, with a market price of $29.61 compared to a fair value estimate of $21.36.
What is OSCR's P/E ratio?
The current P/E ratio for Oscar Health is 21.1x, which is significantly lower than its 5-year median P/E of 45.7x, suggesting it is trading below its historical valuation despite being considered overvalued based on GF Valueâ„¢.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
